Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
sustain most of their weight loss after switching from the company's injection Zepbound and Novo Nordisk's Wegovy in a late-stage study. Is LLY fairly valued? Test your thesis with our free DCF calculator. The phase three study examined over 300 obese individuals who had GLP-1 injections for 72 weeks before switching to the oral medication or a placebo. The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli Lilly claimed the findings show orforglipron's potential as a weight reduction maintenance medication without weekly injections. It filed the tablet for FDA clearance, which got priority consideration in November. The tablet mimics gut hormone GLP-1 to reduce hunger and manage blood sugar, making it simpler to absorb and less restrictive than peptide-based medications like Wegovy and Ozempic Analysts expect the worldwide obesity drug industry to reach $95 billion by 2030, with tablets accounting for 24%.
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
- Obesity pill race heats up [CNBC]CNBC
- Lilly says obesity pill can replace shot after weight loss [Yahoo! Finance]Yahoo! Finance
- Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma's Expanding Role [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk (NVO) Fell Following a Profit Warning Release [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website